KR101921436B1 - 인자 XIa 억제제로서의 피리미디논 - Google Patents

인자 XIa 억제제로서의 피리미디논 Download PDF

Info

Publication number
KR101921436B1
KR101921436B1 KR1020177011233A KR20177011233A KR101921436B1 KR 101921436 B1 KR101921436 B1 KR 101921436B1 KR 1020177011233 A KR1020177011233 A KR 1020177011233A KR 20177011233 A KR20177011233 A KR 20177011233A KR 101921436 B1 KR101921436 B1 KR 101921436B1
Authority
KR
South Korea
Prior art keywords
mmol
chloro
pharmaceutically acceptable
independently selected
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177011233A
Other languages
English (en)
Korean (ko)
Other versions
KR20170057431A (ko
Inventor
앤드루 케이. 딜거
제임스 알. 코트
인다와티 드 루카
티아난 팡
우 양
위펑 왕
쿠마르 발라샨무가 파비세티
윌리엄 알. 유잉
예헝 주
루스 알. 웩슬러
도널드 제이.피. 핀토
마이클 제이. 오르왓
레온 엠. 스미스 2세
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Priority to KR1020187033199A priority Critical patent/KR102269999B1/ko
Publication of KR20170057431A publication Critical patent/KR20170057431A/ko
Application granted granted Critical
Publication of KR101921436B1 publication Critical patent/KR101921436B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020177011233A 2014-10-01 2015-07-29 인자 XIa 억제제로서의 피리미디논 Active KR101921436B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020187033199A KR102269999B1 (ko) 2014-10-01 2015-07-29 인자 XIa 억제제로서의 피리미디논

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462058316P 2014-10-01 2014-10-01
US62/058,316 2014-10-01
PCT/US2015/042576 WO2016053455A1 (en) 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033199A Division KR102269999B1 (ko) 2014-10-01 2015-07-29 인자 XIa 억제제로서의 피리미디논

Publications (2)

Publication Number Publication Date
KR20170057431A KR20170057431A (ko) 2017-05-24
KR101921436B1 true KR101921436B1 (ko) 2018-11-22

Family

ID=53784023

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177011233A Active KR101921436B1 (ko) 2014-10-01 2015-07-29 인자 XIa 억제제로서의 피리미디논
KR1020187033199A Active KR102269999B1 (ko) 2014-10-01 2015-07-29 인자 XIa 억제제로서의 피리미디논

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187033199A Active KR102269999B1 (ko) 2014-10-01 2015-07-29 인자 XIa 억제제로서의 피리미디논

Country Status (34)

Country Link
EP (4) EP3089979B1 (cg-RX-API-DMAC7.html)
JP (4) JP6462865B2 (cg-RX-API-DMAC7.html)
KR (2) KR101921436B1 (cg-RX-API-DMAC7.html)
CN (3) CN110734435B (cg-RX-API-DMAC7.html)
AR (1) AR101367A1 (cg-RX-API-DMAC7.html)
AU (3) AU2015324530B2 (cg-RX-API-DMAC7.html)
CA (1) CA2963395C (cg-RX-API-DMAC7.html)
CL (1) CL2017000712A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017003833A2 (cg-RX-API-DMAC7.html)
CY (2) CY1119678T1 (cg-RX-API-DMAC7.html)
DK (2) DK3293186T3 (cg-RX-API-DMAC7.html)
EA (1) EA031590B1 (cg-RX-API-DMAC7.html)
ES (3) ES2836270T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20171950T1 (cg-RX-API-DMAC7.html)
HU (2) HUE038061T2 (cg-RX-API-DMAC7.html)
IL (2) IL251434B (cg-RX-API-DMAC7.html)
LT (2) LT3293186T (cg-RX-API-DMAC7.html)
MA (1) MA40123A1 (cg-RX-API-DMAC7.html)
MX (2) MX376056B (cg-RX-API-DMAC7.html)
MY (2) MY201397A (cg-RX-API-DMAC7.html)
NO (1) NO2721243T3 (cg-RX-API-DMAC7.html)
PE (2) PE20210922A1 (cg-RX-API-DMAC7.html)
PH (2) PH12017500580B1 (cg-RX-API-DMAC7.html)
PL (1) PL3089979T3 (cg-RX-API-DMAC7.html)
PT (2) PT3293186T (cg-RX-API-DMAC7.html)
RS (2) RS56786B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201702576QA (cg-RX-API-DMAC7.html)
SI (2) SI3089979T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201800021T1 (cg-RX-API-DMAC7.html)
TN (2) TN2017000112A1 (cg-RX-API-DMAC7.html)
TW (3) TWI692478B (cg-RX-API-DMAC7.html)
UY (1) UY36244A (cg-RX-API-DMAC7.html)
WO (1) WO2016053455A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201702478B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JP6505727B2 (ja) * 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
NO2760821T3 (cg-RX-API-DMAC7.html) 2014-01-31 2018-03-10
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
AU2015327345B9 (en) 2014-10-01 2020-06-18 Merck Patent Gmbh Boronic acid derivatives
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors
ES2871111T3 (es) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
CN107849026B (zh) * 2015-07-29 2021-01-01 百时美施贵宝公司 携带烷基或环烷基p2′部分的因子xia大环抑制剂
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN109195973A (zh) 2016-03-02 2019-01-11 百时美施贵宝公司 具有因子xia抑制活性的二酰胺大环类化合物
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
CN110062757B (zh) * 2017-01-18 2022-03-04 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EP4234555A3 (en) * 2019-04-11 2024-01-03 Bristol-Myers Squibb Company Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one
KR20210151183A (ko) * 2019-04-11 2021-12-13 브리스톨-마이어스 스큅 컴퍼니 치료 혈장 농도를 달성하기 위한 무정형 고체 및 가용화된 제제의 증진된 성능
CN113677682B (zh) * 2019-04-16 2023-05-30 华润生物医药有限公司 作为XIa因子抑制剂的大环衍生物
WO2021013209A1 (zh) 2019-07-23 2021-01-28 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
EP4036087A4 (en) * 2019-09-27 2023-09-20 Shenzhen Salubris Pharmaceuticals Co. Ltd FXA INHIBITORS AND METHODS OF PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF
PH12022551160A1 (en) 2019-11-15 2023-09-25 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease
WO2021207659A1 (en) * 2020-04-10 2021-10-14 Bristol-Myers Squibb Company Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one
CN119552111B (zh) * 2020-07-29 2026-01-02 上海柯君医药科技有限公司 抗血小板药物和其用途
EP4225757A1 (en) * 2020-10-12 2023-08-16 Bristol-Myers Squibb Company A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one
TW202241964A (zh) * 2021-01-08 2022-11-01 美商必治妥美雅史谷比公司 因子xia抑制劑之抗體及抗原結合肽及其用途
CN115215867B (zh) * 2021-04-21 2023-12-26 上海美悦生物科技发展有限公司 FXIa抑制剂及其药物组合物、制备方法和用途
TW202515882A (zh) * 2023-06-30 2025-04-16 大陸商深圳信立泰藥業股份有限公司 一種多取代的大環化合物及其製備方法與應用
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022767A1 (en) 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
JP5844287B2 (ja) * 2010-02-11 2016-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としてのマクロ環
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
US9327839B2 (en) * 2011-08-05 2016-05-03 General Atomics Method and apparatus for inhibiting formation of and/or removing ice from aircraft components
WO2013093484A1 (en) * 2011-12-21 2013-06-27 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
CA2880898A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
JP6505727B2 (ja) * 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
NO2760821T3 (cg-RX-API-DMAC7.html) * 2014-01-31 2018-03-10
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022767A1 (en) 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors

Also Published As

Publication number Publication date
PH12020500195A1 (en) 2021-02-08
CN106795161A (zh) 2017-05-31
MY201397A (en) 2024-02-21
ES2963267T3 (es) 2024-03-26
JP6937734B2 (ja) 2021-09-22
WO2016053455A1 (en) 2016-04-07
KR20170057431A (ko) 2017-05-24
TN2017000112A1 (en) 2018-07-04
IL251434A0 (en) 2017-05-29
SMT202000667T1 (it) 2021-01-05
ZA201702478B (en) 2019-06-26
JP6462865B2 (ja) 2019-01-30
CN110734435B (zh) 2022-06-07
EA201790595A1 (ru) 2017-07-31
KR102269999B1 (ko) 2021-06-25
CO2017003833A2 (es) 2017-07-11
EP3089979A1 (en) 2016-11-09
PH12017500580A1 (en) 2017-08-30
TWI834182B (zh) 2024-03-01
EP3828186A2 (en) 2021-06-02
EP3293186A1 (en) 2018-03-14
AU2020200376B2 (en) 2021-07-08
PE20210922A1 (es) 2021-05-19
JP2019069989A (ja) 2019-05-09
CY1119678T1 (el) 2018-04-04
LT3293186T (lt) 2020-12-28
EP3828186A3 (en) 2021-07-28
TWI769442B (zh) 2022-07-01
NO2721243T3 (cg-RX-API-DMAC7.html) 2018-10-20
ES2836270T3 (es) 2021-06-24
IL276470A (en) 2020-09-30
PE20170939A1 (es) 2017-07-13
IL276470B (en) 2021-04-29
CL2017000712A1 (es) 2017-11-03
AU2015324530A1 (en) 2017-05-18
CN114957255A (zh) 2022-08-30
EA031590B1 (ru) 2019-01-31
LT3089979T (lt) 2017-12-27
CN106795161B (zh) 2019-10-15
PT3293186T (pt) 2020-12-09
MA40123A1 (fr) 2017-09-29
MY183987A (en) 2021-03-17
EP4286372A3 (en) 2024-02-21
JP2021185182A (ja) 2021-12-09
BR112017006702A2 (pt) 2017-12-26
HUE052812T2 (hu) 2021-05-28
CN110734435A (zh) 2020-01-31
AU2021245098A1 (en) 2021-10-28
KR20180126612A (ko) 2018-11-27
RS56786B1 (sr) 2018-04-30
MX376056B (es) 2025-03-07
UY36244A (es) 2016-01-29
AU2015324530B2 (en) 2019-10-24
JP2017530157A (ja) 2017-10-12
CA2963395A1 (en) 2016-04-07
EP4286372A2 (en) 2023-12-06
EP3089979B1 (en) 2017-10-18
TN2018000229A1 (en) 2019-10-04
EP3828186B1 (en) 2023-08-23
TWI692478B (zh) 2020-05-01
TW201613923A (en) 2016-04-16
HUE038061T2 (hu) 2018-09-28
ES2655884T3 (es) 2018-02-22
SI3089979T1 (sl) 2017-12-29
RS61183B1 (sr) 2021-01-29
TW202310844A (zh) 2023-03-16
JP7317905B2 (ja) 2023-07-31
PH12017500580B1 (en) 2020-10-09
NZ731416A (en) 2024-01-26
PL3089979T3 (pl) 2018-02-28
SG10201911652TA (en) 2020-02-27
EP3293186B1 (en) 2020-09-23
SG11201702576QA (en) 2017-04-27
SI3293186T1 (sl) 2021-01-29
IL251434B (en) 2020-08-31
JP2023134734A (ja) 2023-09-27
HRP20201927T1 (hr) 2021-02-05
CA2963395C (en) 2023-03-14
AR101367A1 (es) 2016-12-14
MX2020010840A (es) 2020-11-06
DK3089979T3 (en) 2018-01-15
AU2020200376A1 (en) 2020-02-06
NZ766570A (en) 2024-01-26
HRP20171950T1 (hr) 2018-02-23
PT3089979T (pt) 2018-01-16
MX2017003695A (es) 2017-05-30
AU2021245098B2 (en) 2023-11-23
CY1123663T1 (el) 2022-03-24
TW202043228A (zh) 2020-12-01
DK3293186T3 (da) 2020-12-14
SMT201800021T1 (it) 2018-03-08

Similar Documents

Publication Publication Date Title
JP7317905B2 (ja) 第ｘｉａ因子阻害剤としてのピリミジノン
JP6630004B2 (ja) 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
KR102697816B1 (ko) 신규 치환된 글리신 유도된 fxia 억제제
KR20150038372A (ko) 인자 XIa 억제제로서의 디히드로피리돈 P1
KR20150038369A (ko) 인자 XIa 억제제로서의 디히드로피리돈 P1
KR102086934B1 (ko) 알킬 또는 시클로알킬 P2' 모이어티를 갖는 인자 XIa 마크로시클릭 억제제
KR102729666B1 (ko) 비-방향족 P2' 기를 갖는 인자 XIa 신규 마크로사이클
KR20180117156A (ko) 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클
HK40053570B (en) Pyrimidinones as factor xia inhibitors
HK40053570A (en) Pyrimidinones as factor xia inhibitors
BR112017006702B1 (pt) Pirimidinonas inibidoras de fator xia, composição farmacêutica e seu uso
HK1227032A1 (en) Pyrimidinones as factor xia inhibitors
HK1227032B (en) Pyrimidinones as factor xia inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20211015

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20221017

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8